STOCK TITAN

Aprea Therapeutics to Present at H.C. Wainwright Global Investment Conference

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Aprea Therapeutics (NASDAQ:APRE), a clinical-stage biopharmaceutical company focused on developing innovative cancer treatments, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference.

The presentation is scheduled for Tuesday, September 9, 2025, at 3:30 PM ET at the Lotte New York Palace Hotel in New York. A webcast of the presentation will be accessible for 90 days through the company's investor relations website.

Loading...
Loading translation...
Argus Aug 28 session
-0.94% close to close 1.1x rel. volume Open Argus
Details

News Market Reaction – APRE

On Aug 28, the day this news came out, APRE closed 0.94% below the previous close.

Data tracked by StockTitan Argus for the Aug 28 session.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

DOYLESTOWN, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today announced that management will present at the H.C. Wainwright 27th Annual Global Investment Conference, to take place September 8-10, 2025, in New York.

Presentation Details

Date/ time: Tuesday, September 9 at 3:30 PM ET
Location: Lotte New York Palace Hotel
Webcast link: click here

The webcast will be available for 90 days at the link above or on the Aprea Investors page, under “News & Events.”

About Aprea
Aprea’s mission is to develop novel cancer therapies that target cancer cells directly, while sparing healthy ones. By exploiting unique vulnerabilities in cancer cell mutations, this approach is designed to eradicate tumors while minimizing harm to normal tissues, thereby reducing the risk of toxicity often associated with conventional chemotherapy and other treatments. Aprea’s lead programs include APR-1051, an oral, small-molecule inhibitor of WEE1 kinase, and ATRN-119, a macrocyclic small molecule ATR inhibitor, both currently in clinical development for solid tumor indications. For more information, please visit the company website at www.aprea.com.

The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Investor Contact:

Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Aprea Therapeutics (APRE) presenting at the H.C. Wainwright Conference?

Aprea Therapeutics will present on Tuesday, September 9, 2025, at 3:30 PM ET at the Lotte New York Palace Hotel in New York.

How long will the APRE conference presentation webcast be available?

The webcast will be available for 90 days through both the conference link and Aprea's Investors page under 'News & Events.'

What is Aprea Therapeutics' (APRE) main business focus?

Aprea is a clinical-stage biopharmaceutical company that develops innovative cancer treatments targeting specific cancer cell vulnerabilities while minimizing damage to healthy cells.

Where can investors access Aprea Therapeutics' H.C. Wainwright presentation?

Investors can access the presentation through the webcast link provided or on the Aprea Investors page under the 'News & Events' section.

Keep reading